Koios Pharmaceuticals files challenge to high-cost drug’s patent

21 July 2016

California, USA-based Koios Pharmaceuticals announced that it has filed a challenge to the validity of US Patent 8,644,231, the sole Orange-Book listed patent protecting Rasuvo - a methotrexate autoinjector product marketed by the US subsidiary of privately-held German firm medac GmbH - from generic competition.

Koios further announced that it has entered into a confidential development and commercialization partnership with a leading developer of sterile injectable pharmaceutical products to introduce a generic equivalent to Rasuvo.

Rasuvo is approved in the USA for the treatment of inflammatory autoimmune diseases including rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis in children.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >